Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective conscientiously but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past few shares of mine. My first CytoDyn post, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire employment interview that I came away with an inadequate impression of the business.

Irony of irony, my poor viewpoint of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology and connected intellectual property coming from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) plus the very first new drug application approval ($five million), as well as royalty payments of five percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it has this single therapies and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications and multiple delivering presentations.

Can it all be smoke and mirrors? That’s a question I have been asking myself from the really start of my interest in this company. Judging by way of the multiples of a huge number of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *